S-ADENOSYL METHIONINE REGULATION OF METABOLIC PATHWAYS AND ITS USE IN DIAGNOSIS AND THERAPY
Patent №
US 6,020,139
Granted
2000-02-01
Filed 1995
Owner
ORIDIGM CORPORATION
+1 more
Lab
—
AI components
1
planning
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
08428963
A new paradigm of disease centers around the metabolic pathways of S-adenosyl-L-methionine (SAM), the intermediates of these pathways and other metabolic pathways influenced by the SAM pathways. Methods are provided to analyze and modulate SAM pathways associated with a disease or condition. Such methods permit identification and utilization of diagnostic and therapeutic protocols and agents for such disease states and conditions.
AI classification
Ownership
ORIDIGM CORPORATION
assignment · 75250214
MEDIQUEST THERAPEUTICS, INC.
namechg · 144990213
Assignors
SCHWARTZ, DENNIS E., VERMEULEN, NICOLAAS M.J., O'DAY, CHRISTINE L.
On an employer assignment, the assignors are typically the inventors.